FIGS is the category-defining premium scrubs brand with improving fundamentals—but its ~100x forward P/E leaves investors underwriting perfect execution amid tariff and commoditization risk.
Overview
FIGS is the category-defining, digitally native premium healthcare apparel brand that transformed scrubs from a utilitarian uniform into a lifestyle-adjacent product, earning a “brand halo” comparison to Lululemon/Nike within its niche. By late December 2025 it serves ~2.8M active customers (“Awesome Humans”) and is transitioning from pandemic-era hyper-growth to a more complex scaling phase. The current investment setup is a tug-of-war between proven brand equity and the operational challenge of diversifying growth as the US online market matures. Management’s strategic pivot centers on (1) building omnichannel access through “Community Hubs,” (2) scaling international revenue (now the fastest-growing geography), and (3) expanding into institutional sales via the TEAMS platform. Financially, signs of stabilization and improved quality are evident: Q3 2025 revenue was $151.7M (+8.2% YoY), above guidance/consensus, and gross margin reached 69.9% (+280 bps YoY), demonstrating pricing power and better freight/inventory execution; EBITDA leverage improved sharply (12.4% margin). The core concern is valuation: at ~$11.87 the stock carries a demanding multiple (forward P/E ~106x; EV/EBITDA ~48x), leaving limited room for execution errors, while the most material external risk is potential reciprocal tariffs on textile imports (notably Vietnam), which could materially compress margins and derail the bull-case math. The report frames FIGS as a high-quality, debt-free franchise with a strong balance sheet—but one where investors must underwrite near-perfect execution in international and B2B growth while navigating geopolitical and competitive headwinds.